Imagine living with a genetic disease that could cause blindness in your 40s—and your doctor tells you there are no treatment options. It's for patients like these that Johnson & Johnson is harnessing cutting-edge technology in the hope of finding real solutions.
Emmanuelle Charpentier, Ph.D., and Jennifer Doudna, Ph.D., were just honored with the prestigious award for their work with gene-editing technology CRISPR. But they also have a connection to Johnson & Johnson—they were awarded the Dr. Paul Janssen Award in 2014. Learn more about what makes them so impressive.
It's been in the news, but what does CAR-T really mean for patients? Immuno-oncology expert Iqbal Grewal, Ph.D., explains why the treatment has the potential to be a game changer for people with all types of cancer down the road.